Compare Citius Pharmaceuticals Inc (CTXR) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Vanguard Information Technology Index Fund ETF trades at $127.98 (market cap $170.20B). The key difference: Vanguard Information Technology Index Fund ETF is far larger — about 12496.3× Citius Pharmaceuticals Inc's market cap, and Vanguard Information Technology Index Fund ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Vanguard Information Technology Index Fund ETF for 129 Days on average.
| CTXR | VGT | |
|---|---|---|
Market Cap | $13.62M | $170.20B |
Volume | 132,438 | 5,132,883 |
Sector | Health | — |
52-Week High | $1.82 | $129.79 |
52-Week Low | $0.48 | $83.59 |
Typical Hold Time | 17 Days | 129 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% in the last session, with a bearish technical signal from moving averages but bullish oscillators. The company reported $7.1M revenue for the first nine months of fiscal 2026 from LYMPHIR sales, yet net losses persist, with a net income margin of -651.27%. Cash flow remains positive due to financing activities, and analyst consensus is strongly bullish with five buy ratings.
The outlook hinges on commercial execution of LYMPHIR, offering growth potential amid high losses. Key risks include sustained negative profitability, cash burn, and competitive pressures. Investors should weigh the speculative growth narrative against fundamental weaknesses.
VGT trades at $127.25, down 1.64% today but maintains a bullish technical outlook with strong moving average support. The ETF has demonstrated exceptional long-term performance with historical annual returns exceeding 17% over two decades, driven by technology sector leadership. Recent news highlights institutional accumulation and dividend distributions, though key financial ratios remain undisclosed.
The outlook remains positive given technology sector momentum and institutional confidence, but investors face concentration risk in top holdings and potential sector volatility. The ETF's low expense ratio provides a competitive advantage, though classification rules exclude major tech names like Google and Amazon, creating portfolio construction considerations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
